Please login to the form below

Not currently logged in
Email:
Password:

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Roche reports continued growth in Q3, despite biosimilar competition

Roche reports continued growth in Q3, despite biosimilar competition

This “progress of our product pipeline” likely hints to Roche’s  $4.3bn acquisition of Spark Therapeutics earlier this year, which has faced continued  delays. ... This is mainly due to ongoing scrutiny from regulatory authorities, with the main

Latest news

More from news
Approximately 14 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... of a more stable adeno-associated virus (AAV) – which now forms the basis of Spark Therapeutics’ drugs and,

  • Health on instalment Health on instalment

    For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...

Infographics